André Wyss appointed new CEO
As part of its long-term planning process, the Board of Directors has appointed André Wyss as the successor to Anton Affentranger. The 51-year-old Swiss will take over at the helm of the company on 1 October 2018. Now his successor has been appointed, Anton Affentranger is to step down as CEO on 30 September 2018.
The new CEO André Wyss has decades of international management experience in a variety of roles. Until spring 2018, he was a member of Novartis’ Executive Committee. As the President of Novartis Operations, André Wyss was responsible for all of Novartis’ manufacturing, shared services and corporate affairs, with almost 40 000 employees worldwide. He was also Country President of Novartis Switzerland.
The departing CEO Anton Affentranger was one of the key figures involved in founding and developing Implenia. Based on the company’s strong domestic market in Switzerland, Anton Affentranger developed an international strategy, which focused on Germany and Austria as well as the Scandinavian countries. This strategy involved a number of notable takeovers: Sulzer Immobilien AG in 2009, Betonmast Anlegg in 2010, Bilfinger Construction in 2015 and Bilfinger Hochbau in 2017.
Audun Aaland new CEO of Implenia Norge
On 1 July 2018, Audun Aaland has taken over as CEO of the Norwegian subsidiary Implenia Norge. His predecessor, Tone H. Bachke will leave Implenia in summer 2018. Audun Aaland is an outstanding expert in construction, and has in-depth knowledge of the Norwegian market. Prior to his time at Implenia, he was Managing Director of Bilfinger Construction in Norway.